摘要：Correction to:
Scientific Reports 10.1038/srep09604, published online 08 April 2015
This Article contains an error in Figure 6, where the incorrect image was used for Figure 6c. The correct Figure
6 and its accompanying legend appear below.
Figure 6
Terminal differentiation induction by mTOR-inactivation decreases SSEA-4
+ TICs in vivo. (
a) SSEA-4
+ cells (1–50 × 10
5) from the different resources as indicated were subcutaneously inoculated into NOD/SCID mice. The oral administration of PBS (filled box) or 5 mg/kg RAD001 (filled circle) commenced 2 days later. Tumor volumes are shown as the means ± SDs, n = 3–5. (
b,
c) Representative images of whole-body (
b) or lung metastasis (
c) bioluminescence 4 weeks following subcutaneous (
b) or tail vein injection (
c) of 1 × 10
5 PBS- or RAD001-treated SSEA-4
+ Well5 cells (as in (
a)) into NOD/SCID mice. (
d) Two representative tissue samples retrieved from the PBS-treated and RAD001-treated groups, respectively. (
e) Immunohistochemical staining of p-S6, SSEA-4, or OCN in xenografts retrieved from the PBS-or RAD001-treated group, as in (
a,
b). Scale bars represent 100 μm. HE: hematoxylin–eosin. (
f) Secondary tumorigenic xenograft formation of tumor tissue or cells after post-PBS or -RAD001 treatment, as in (
a,
b) (upper panel). Secondary tumorigenic xenografting rates (n/n) are summarized in the bottom table (
P < 0.01).
